Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that UK-based Ark Therapeutics Group plc (LSE: AKT) has decided to renew its PER.C6® technology licensing agreement. Under the renewed agreement, the parties have negotiated research and also commercial terms for Ark's development and manufacture of gene-based medicine using Crucell's PER.C6® technology.
